The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non-small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials

• Main Authors: Cheng-Qiong Wang (Author), Xiao-Tian Zheng (Author), Xiao-Fan Chen (Author), Hong Jiang (Author), Jun Huang (Author), Yuan Jiang (Author), Shan-Shan Hu (Author), Xiao-Rong Huang (Author), Shi-Yu Liu (Author), Qi-Hai Gong (Author), Ji-Hong Feng (Author), Xue Xiao (Author), Xiao-Fei Li (Author), Zheng Xiao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Aidi injection (Aidi) is composed of cantharidin, astragaloside, ginsenoside, and elentheroside E. As an important adjuvant therapy, Aidi in combination with gemcitabine and cisplatin (GP) is often used in the treatment of non-small cell lung cancer (NSCLC).Objectives: We performed a n...